SEQUENT SCIENTIFIC LTD.

Viyash Scientific Limited announced its Q1 FY27 financial results, reporting a significant 19.5% increase in revenues to ₹9,464 million. EBITDA grew by 59.2% to ₹2,047 million, and Profit After Tax (PAT) surged by 114.9% to ₹793 million. The company highlighted robust growth driven by integration efforts and strategic acquisitions, such as Bio For Life in Italy, which strengthens its companion animal segment presence in Europe. The Net Debt to EBITDA ratio stood at a healthy 0.1x. The company will host an earnings call on August 12, 2026, to discuss performance and future outlook.

Viyash Scientific Ltd's Board of Directors met on August 11, 2026, approving the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, along with the auditor's limited review report. The Board also approved the allotment of 10,30,775 equity shares under the ESOP Scheme 2026, increasing the company's paid-up capital. Additionally, the company will incorporate a wholly-owned subsidiary in Vietnam and invest up to ₹400.02 crore in its subsidiary Alivira Animal Health Limited (AAHL) through a rights issue to strengthen its capital structure.

Viyash Scientific (formerly Sequent Scientific) reported consolidated revenue of ₹946.4 Cr and PAT of ₹79.3 Cr for the quarter ended 30 June 2026, its first full quarter reporting under the enlarged post-amalgamation structure. Against the filing's own restated year-ago base (₹791.6 Cr revenue, ₹36.9 Cr PAT — restated to include the merged Viyash Life Sciences/Symed Labs group), that is +19.5% revenue and +115% PAT YoY (~110% adjusted for a negligible ₹1.25 Cr prior-year scheme cost); against the previously-tracked pre-merger Q1 FY26 base (₹441.4 Cr revenue, ₹17.6 Cr PAT) the jump looks far larger (+114%/+351%), but that gap is a consolidation-perimeter effect from the NCLT-sanctioned amalgamation (effective 16 December 2025), not underlying business growth. Sequentially, revenue rose 2.9% and PAT 19.4% over Q4 FY26 (₹919.96 Cr / ₹66.38 Cr). Margins expanded on both comparisons: consolidated net margin rose to 8.4% from 4.65% (YoY restated) and 7.09% (QoQ), while EBITDA margin (PBT + finance cost + depreciation − other income, over revenue) improved to 18.85% from 14.85% YoY restated, though it eased from 20.03% in Q4 FY26. The QoQ margin dip sits partly on the employee-cost line, which absorbed roughly ₹19.3 Cr of incremental expense from the new 2026 ESOP scheme (1.31 Cr options granted this quarter, 2.8% of post-amalgamation paid-up capital). Standalone results were far smaller in scale — ₹353.7 Cr revenue, ₹20.9 Cr PAT, EPS ₹0.48 — underscoring that the bulk of profitability now sits in the Alivira Animal Health international subsidiaries (Spain, Brazil, Turkey, Mexico, UK and others) folded into the consolidated numbers. On management's own framing: the prior (Q4 FY26) call targeted ~15% growth and a longer-term path to ₹1,000 Cr EBITDA while holding current margins through R&D and capacity investment. This quarter's restated organic revenue growth (19.5%) exceeds that 15% bar, and the EBITDA margin, while off its Q4 peak, sits well above the year-ago restated level — consistent with, not contradicting, that guidance; no formal Street consensus estimate for this specific quarter could be located, so vsStreet is marked unknown rather than guessed. No separate management press release was available in the context to quote directly. The board used the same meeting to approve several structural items with no direct P&L impact this quarter: allotment of 10.3 lakh ESOP shares, incorporation of a step-down Vietnam subsidiary via Alivira Animal Health, and subscription of up to ₹400 Cr into AAHL (India) via conversion of intercompany loans to equity to strengthen its capital structure. Separately, a step-down subsidiary signed an SPA on 21 July 2026 to acquire BioForLife Italia (~EUR 17 Mn), also with no impact on this quarter's results. Going into Q2 FY27, the print sets up two things to track: whether the EBITDA margin re-approaches the 20% Q4 FY26 level or settles near the current ~19% once the ESOP expense annualises, and how quickly the Vietnam entity, BioForLife Italia deal and AAHL rights issue move from board approvals to consolidated financial contributors.

Viyash Scientific Ltd has announced that its Board of Directors will convene on August 11, 2026, to consider and approve the unaudited standalone and consolidated financial results for the first quarter ended June 30, 2026. The company also informed that the trading window for its securities will remain closed from July 01, 2026, until 48 hours after the declaration of these financial results, extending up to August 13, 2026, in accordance with its insider trading code.

Viyash Scientific Limited's step-down subsidiary, Alivira Animal Health Limited, Ireland, has executed a Sale and Purchase Agreement (SPA) to acquire 100% of BioForLife Italia S.r.l. The base consideration is approximately EUR 16.976 million, comprising EUR 15 million at closing and EUR 1.976 million as retained/deferred consideration. The deferred consideration mechanism has been revised and is linked to contractual continuation conditions. Transaction completion is subject to Italian FDI/Golden Power clearance and other SPA conditions. This disclosure confirms the execution of definitive transaction documentation.

Viyash Scientific Limited (formerly SeQuent Scientific Limited) has announced its 41st Annual General Meeting (AGM) scheduled for Tuesday, August 11, 2026, at 4:00 PM IST, to be held via Video Conference (VC) / Other Audio-Visual Means (OAVM). This is in compliance with recent Ministry of Corporate Affairs (MCA) circulars. The Notice of the AGM and the Annual Report for FY 2025-26 are being disseminated electronically to members with registered email addresses. For members whose email IDs are not registered, a letter providing a web-link to the Annual Report and AGM Notice is being sent. The report and notice are also available on the company's website (www.viyash.com), stock exchange websites (BSE, NSE), and NSDL's e-voting platform. Members are encouraged to register their email addresses for future electronic communications and update their KYC details.

Viyash Scientific Limited has submitted its Business Responsibility and Sustainability Reporting (BRSR) for the Financial Year 2025-26, as mandated by SEBI regulations. The report, available on the company's website, details its operations, products, and workforce. Key disclosures include its primary business in pharmaceuticals, manufacturing Active Pharmaceutical Ingredients (APIs) and formulations, contributing 100% to turnover. The company serves both B2B and B2C markets globally, with exports accounting for 43.05% of total turnover. The report also provides employee statistics, noting a total of 2,568 employees and 1,563 workers, with specific data on differently-abled individuals.

Viyash Scientific Ltd has issued a notice for its 41st Annual General Meeting (AGM), scheduled for Tuesday, August 11, 2026, at 4:00 PM IST. The meeting will be conducted via Video Conferencing (VC) / Other Audio-Visual Means (OAVM). Shareholders can access the AGM notice on the company's website. A remote e-voting facility will be available from Friday, August 7, 2026, 9:00 AM IST, until Monday, August 10, 2026, 5:00 PM IST. The cut-off date for e-voting eligibility is Tuesday, August 04, 2026. The AGM agenda includes considering and adopting the Audited Standalone and Consolidated Financial Statements for the fiscal year ended March 31, 2026, and the re-appointment of Dr. Haribabu Bodepudi and Mr. Rajaram Narayanan as directors.

Viyash Scientific Ltd has filed its Annual Report for FY 2025-26 and announced the 41st Annual General Meeting (AGM). The AGM is scheduled for August 11, 2026, at 4:00 PM IST, to be held via Video Conferencing. Shareholders can access the AGM notice and annual report on the company's website. E-voting facilities are available from August 7 to August 10, 2026, with a cut-off date of August 4, 2026, for voting eligibility. The report highlights the company's integrated global pharmaceutical platform, combining human and animal health capabilities, and outlines performance, segment reviews, and sustainability commitments for FY26.

Viyash Scientific Ltd has disclosed receiving an administrative warning letter from the Securities and Exchange Board of India (SEBI). The warning pertains to the maintenance of the Structured Digital Database (SDD) for the period June 26, 2024, to October 18, 2024, under SEBI (Prohibition of Insider Trading) Regulations, 2015. The issue relates to an observation regarding the completeness of information in the SDD during the specified period. The company states there is no impact on its financial, operational, or other activities as a result of this warning. The letter was received on July 7, 2026.